|
Influenza
|
0.020 |
Biomarker
|
disease |
BEFREE |
Previous studies indicated that Actinobacillus pleuropneumoniae PalA is homologous to a Haemophilus influenzae protective antigen Hi-PAL (P6) protein.
|
28828973 |
2017 |
|
Influenza
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the sequence had a high degree of similarity to the peptidoglycan-associated outer membrane lipoprotein P6 of Haemophilus influenzae and the peptidoglycan-associated lipoprotein PAL of E. coli.
|
8576327 |
1995 |
|
Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Anorexia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Nausea
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
cocaine use
|
0.010 |
Biomarker
|
disease |
BEFREE |
3-Fluoroamphetamine (also called PAL-353) is a synthetic amphetamine analog that has been investigated for cocaine use disorder (CUD), yet no studies have characterized its pharmacokinetics (PK).
|
31642004 |
2020 |
|
Gingivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAL-V achieved by regenerative therapy in infrabony defects is as stable over 5 years as periodontally reduced but gingivally healthy or gingivitis sites.
|
30972774 |
2019 |
|
Trematode Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Although sensitive to distomatosis, γGT and PAL values were inconsistent with the infection rate.
|
30689191 |
2019 |
|
Caffeine related disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The comparison of TGY vs. BS revealed eight up-regulated genes (PAL, C4H, CHS, F3'H, F3H, DFR, ANS, and ANR) and two down-regulated genes (FLS and CCR) in flavonoid metabolism, four up-regulated genes (AMPD, IMPDH, SAMS, and 5'-Nase) and one down-regulated XDH gene in caffeine metabolism; and two down-regulated genes (ALDH and HIBADH) in limonene degradation.
|
30943892 |
2019 |
|
Skin callus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Phytochemical analysis of the callus cultures showed higher production of phenolics (TPC:3.0 mg), flavonoids (TFC:1.8 mg), phenylalanine ammonialyase activity (PAL: 5.8 U/mg) and antioxidant activity (90%), respectively, in the callus cultures established on MS media in the presence of 90 ug/l AgNPs.
|
30856344 |
2019 |
|
psychosocial stressor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
PA data were collected with the accelerometer ActiGraph GT3X (Pensacola, FL, USA), SED data with the inclinometer activPAL (PAL Technologies Ltd., Glasgow, Scotland, UK), and psychosocial stressors with a web questionnaire.
|
31547253 |
2019 |
|
Respiratory Failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, the current P-PAL design met our pumping, oxygenation, and hemolysis specifications and has the potential to improve treatment for pediatric respiratory failure.
|
29240630 |
2019 |
|
Mental Depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Depressive disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PAL project develops a conversational agent with a physical (robot) and virtual (avatar) embodiment to support diabetes self-management of children ubiquitously.
|
29548599 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The PAL project develops a conversational agent with a physical (robot) and virtual (avatar) embodiment to support diabetes self-management of children ubiquitously.
|
29548599 |
2018 |
|
Feeling despair
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Outcome measures were ego-integrity and despair (NEIS), psychological distress, anxiety and depression (HADS), quality of life (EORTC QLQ-C15-PAL), and specificity of the autobiographical memory (AMT).
|
29763431 |
2018 |
|
Depressed mood
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Chronic low back pain
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PAL-S has demonstrated content validity and is potentially useful to assess treatment benefit in cLBP clinical trials.
|
29432327 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prospective QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, Core 15 for Palliative Care (EORTC QLQ-C15-PAL) and liver metastases (LM21), at baseline, 1st week and last day of treatment, then 1, 6 and 12 weeks after SABR.
|
30274721 |
2018 |
|
Classical phenylketonuria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
|
29973227 |
2018 |
|
Bodily Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Convergent validity was demonstrated with PAL-I total score and Roland-Morris Disability Questionnaire (Pearson correlation 0.82), MOS-36 Physical Functioning (-0.71), and MOS-36 Bodily Pain (-0.71).
|
29889120 |
2018 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
A lectin with strong cytotoxic effect on human colon cancer HT29 and monkey kidney VERO cells was recently identified from the Australian indigenous mushroom Psathyrella asperospora and named PAL.
|
28168856 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We retrospectively compared 33 consecutive cases treated with 18-mm-diameter stents (bridge to surgery [BTS] in 25, palliative therapy [PAL] in 8) with 27 consecutive cases treated with 22-mm-diameter stents (BTS in 21, PAL in 6) for obstructive colorectal cancer between May 2013 and November 2015 in our institution.
|
29258112 |
2017 |